Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients

Journal of Surgical Oncology

Volumn 91, Issue 2, 2005, Pages 107-111

  Takkenberg, R B ^a   Vrouenraets, B C ^a   Van Geel, A N ^b   Nieweg, O E ^a   Noorda, E M ^a   Eggermont, A M M ^b   Kroon, B B R ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Isolated limb perfusion; Melanoma; Metastases; Palliation

Indexed keywords

GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CARBON DIOXIDE LASER; CLINICAL ARTICLE; ERYTHEMA; FEMALE; HOSPITALIZATION; HUMAN; LASER SURGERY; LIMB PERFUSION; MALE; MELANOMA; METASTASIS; NERVE INJURY; PERIPHERAL EDEMA; PRIORITY JOURNAL; TIBIAL NERVE; WOUND INFECTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CATHETER ABLATION; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; EXTREMITIES; FEMALE; HUMANS; LENGTH OF STAY; LUNG NEOPLASMS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; REMISSION INDUCTION; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; TOURNIQUETS; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23044517050     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20297     Document Type: Article

References (25)

1. Balch CM, Buzaid AC, Soong S-J, et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
2. Strobbe LJ, Nieweg OE, Kroon BB: Carbon dioxide laser for cutaneous melanoma metastases: Indications and limitations. Eur J Surg Oncol 1997;23:435-438.
3. Hill S, Thomas JM: Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996; 83:509-512.
4. Hafstrom L, Rudenstam CM, Blomquist E, et al.: Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991;9:2091-2094.
5. Kroon B: Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol 1988;14:101-110.
6. Vrouenraets BC, Nieweg OE, Kroon BBR: Thirty-five years of isolated limb perfusion for melanoma: Indications and results. Br J Surg 1996;83:1319-1328.
7. Noorda EM, Takkenberg RB, Vrouenraets BC, et al.: Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma. Ann Surg Oncol 2004;11:491-499.
8. Kapteijn BA, Klaase JM, van Geel AN, et al.: Results of regional isolated perfusion for locally inoperable melanoma of the limbs. Melanoma Res 1994;4:135-138.
9. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002;9:968-974.
10. Fraker DL, Alexander HR, Andrich M, et al.: Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: Results of a tumor necrosis factor dose escalation study. J Clin Oncol 1996;14:479-489.
11. Rossi CR, Foletto M, Pilati P, et al.: Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 2000;29: 400-409.
12. Wieberdink J, Benckhuijsen C, Braat RP, et al.: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-910.
13. WHO: WHO handbook for reporting results of cancer treatment; 1979.
14. Klaase JM, Kroon BB, van Geel AN, et al.: Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994;115:39-45.
15. Di Filippo F, Calabro A, Giannarelli D, et al.: Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989;63:2551-2561.
16. Vrouenraets BC, Hart GA, Eggermont AM, et al.: Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999;188: 522-530.
17. Lejeune FJ: High dose recombinant tumor necrosis factor (rTNF-alpha) administered by isolation perfusion for advanced tumours of the limbs: A model for biochemotherapy of cancer. Eur J Cancer; 31A:6:1009-1016
18. Fraker DL, Alexander HR, Andrich M, et al.: Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1995;1:122.
19. Eton O, Legha SS, Bedikian AY, et al.: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 2002;20: 2045-2052.
20. Keilholz U, Conradt C, Legha SS, et al.: Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 1998;16:2921-2929.
21. Hwu WJ: New approaches in the treatment of metastatic melanoma: Thalidomide and temozolomide. Oncology 2000;14: 25-28.
22. Jacques DP, Coit DG, Brennan MF: Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 1989;169: 1-6.
23. Schraffordt Koops H, Vaglini M, Suciu S, et al.: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. J Clin Oncol 1998;16:2906-2912.
24. Vrouenraets BC, in't Veld GJ, Nieweg OE, et al.: Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol 1999;25:503-508.
25. Sonneveld EJ, Vrouenraets BC, Van Geel BN, et al.: Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol 1999;22:521-527